AstraZeneca has expanded its agreement with cell therapy firm Oxford Biomedica to mass-produce its COVID-19 potential vaccine, as it looks to scale-up supply ahead of a possible U.S. fast-track ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback